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Abstract
Background: Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is
licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis
(RRMS). In three randomized, rater-blinded active comparator clinical trials studies, alemtuzumab administered in two
annual courses, had superior efficacy as compared to subcutaneous interferon beta-1a, and durable efficacy over 5 years
in an extension study with a manageable safety profile in RRMS patients. Data on the utilization and the outcomes of
alemtuzumab under clinical practice conditions are limited.
Methods: Here we describe the rationale, design and methods of the TREAT-MS study (non-interventional long-Term
study foR obsErvAtion of Treatment with alemtuzumab in active relapsing-remitting MS).
Discussion: TREAT-MS is a prospective, multicenter, non-interventional, long-term study to collect data on safety,
effectiveness, quality of life, cognition and other aspects from 3200 RRMS patients treated with alemtuzumab under
the conditions of real-world clinical practice in Germany.
Trial registration: As non-interventional trial in Germany.
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Background
Multiple sclerosis (MS) is generally considered a primarily
T-cell mediated autoimmune disease of the central nervous
system (CNS). To date, no cures exist for MS – the disease
will progress to a worse stadium with higher disability
sooner or later. Only disease course-modifying therapies
(DMTs) are available for patients [1]. Treatments for the
mild and moderate relapsing remitting MS (RRMS) courses
are interferons-β and glatiramer acetate, DMTs which have
been used since 20 years [2, 3]. On average, these injectable
drugs cut the annual relapses by a third, and they are effect-
ive with side effects like flu like symptoms or injection site
reactions [3, 4]. In 2013, teriflunomide [5] and in 2014,
dimethylfumarate [6] have been introduced as oral agents
for RRMS treatment.
Given that first-line therapies might fail to adequately
control disease activity in some patients, it has been rec-
ommended to switch these patients early to a therapy of
higher efficacy more rigorously [7, 8]. Among treatments
for (highly) active RRMS offering higher effectivity but also
* Correspondence: Tjalf.Ziemssen@uniklinikum-dresden.de
1Center of Clinical Neuroscience, Carl Gustav Carus University Hospital,
Dresden, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ziemssen et al. BMC Neurology  (2016) 16:109 
DOI 10.1186/s12883-016-0629-9
accompanied by significant side effects are DMTs such as
fingolimod and natalizumab [9]. Fingolimod reduces the
amount of lymphocytes that exit the lymph node by bind-
ing to sphingosine-1-phosphate receptors on the cell
surface. While annual relapse rates (ARRs) are reduced by
more than half [10], cardiac side effects and macular
edemas are among the side effects [11]. Natalizumab, a
humanized monoclonal anti-α4-integrin antibody, pre-
vents lymphocytes’ crossing the blood-brain barrier [12]. It
was shown that it can reduce ARRs by 68 %; however, an
especially dangerous adverse effect of natalizumab is pro-
gressive multifocal leukoencephalopathy (PML), a brain
infection by the John Cunningham (JC) virus [13]. For this
complication, a lethality of 20 % in MS patients treated
with natalizumab has been reported [14].
Alemtuzumab
Alemtuzumab (Lemtrada®, marketed by Genzyme) has been
approved in Europe 2013 and is marketed as a treatment
for RRMS with active disease defined by clinical or imaging
features [15]. In the USA, the drug has been approved in
November 2014 for RRMS and PRMS treatment, but only
for patients who did not have a satisfying response to two
or more drugs (i.e. for second-line therapy).
Alemtuzumab is a humanized monoclonoal antibody
against the lymphocyte surface protein CD52 [16]. CD52
covers about 5 % of the entire surface of lymphocytes; apart
from them, it occurs on cells as diverse as macrophages
and endothelial cells [17]. After binding of alemtuzumab to
CD52, lymphocytes are destroyed either by complement-
induced or antibody-dependent cell-mediated cytotoxicity
[16, 18, 19]. As a consequence it is assumed that B- and T-
cell repopulation takes place [20] by which – compared
with the pre-treatment stage – the proportions of lympho-
cyte subgroups are shifted; the numbers of regulatory T
cells and memory B- and T-cells are increased, and cell
populations of innate immunity are also affected [21].
Overall, alemtuzumab appears to re-organize the im-
mune repertoire, which manifests in the special kinetics
of immune cell population, the increased production of
antiinflammatory cytokines, and last but not least the
very long duration of action [18, 22].
Three randomized, rater-blinded clinical trials about the
effectiveness of alemtuzumab in MS treatment, using an ef-
fective comparator drug, have been performed, CAMMS223
[23], CARE-MS I [24], and CARE-MS II [25]. Administering
12 mg alemtuzumab per day, CAMMS223 and CARE-MS I
showed a 69 and 55 % higher reduction of relapses than
interferon-β 1a (IFNB-1a). Long-term effectivity of alemtu-
zumab was also superior compared with IFNB-1a: CARE-
MS II showed a reduction of the sustained accumulation of
disability (SAD) within 6 months of 42 % and a reduction of
relapses per year of 49 %. SAD reduction in a 5-year per-
spective was 69 %, and reduction of relapses 66 % in this
long-term outlook [26]. In sum, alemtuzumab drastically
slowed down progression of MS.
Important adverse effects elicited by alemtuzumab are
secondary autoimmune reactions, in particular (for un-
known reasons) reactions targeting the thyroid gland
[27, 28]. In the studies, 26, 18 and 16 %, respectively, of
patients were diagnosed with thyroid autoimmune disease
(AID) [15]. Furthermore, a few cases of Goodpasture
Syndrome were observed [29]. In this AID, the basement
membrane of kidneys is attacked, which can lead to kidney
failure. Idiopathic thrombocytopenic purpura has also been
described as a serious adverse effect, causing severe hemor-
rhages [30–32]. Last, like with natalizumab, reactivation of
the JC virus can lead to potentially lethal PML which has
been reported in hematological diseases where alemtuzu-
mab was often administered concurrently with immuno-
suppressive therapy [33, 34]. Up to now, there was only one
carry over PML MS case switching from natalizumab to
alemtuzumab.
Regular tests before, during and after administration of
alemtuzumab have been recommended to recognize and
terminate further development of such serious adverse
drug reactions [28, 35]. The implementation of a system-
atic safety monitoring program allows for the early detec-
tion and management of autoimmune and other known
events [28].
Rationale of the TREAT-MS study
Randomized controlled trials (RCTs) are the “gold stand-
ard” for generating evidence of the efficacy and safety of a
drug. However, enrolment criteria, timelines, and atypical
comparators of RCTs limit relevance to standard clinical
practice. Real-world data (RWD) provide longitudinal
information on comparative effectiveness and tolerability
of drugs, as well as their impact on resource use, medical
costs, pharmacoeconomic outcomes, and patient-reported
outcomes [36, 37]. Regarding alemtuzumab, the collected
data from clinical studies provide a sound body of
evidence on the efficacy and the safety profile in the treat-
ment of RRMS. However, data on the utilization and the
treatment outcomes of the drug under clinical prac-
tice conditions are limited to few reports on small
cohorts [38, 39].
Here we describe the rationale, design and methods of
the recently established non-interventional open, uncon-
trolled, prospective, multicenter, and long-term study
TREAT-MS (non-interventional long-Term study foR
obsErvAtion of Treatment with Alemtuzumab in active
relapsing-remitting MS).
The main goal of TREAT-MS is to establish a broader
real-world dataset on the utilization and safety, effective-
ness, quality of life and other aspects of the drug in every-
day clinical practice. The study encompasses a risk
management plan to recognize and counter each occurring
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adverse effect as early as possible, which will also support
physicians who treat MS patients with alemtuzumab in
their daily clinical practice [28]. TREAT will additionally in-
vestigate how the risk management plan is transferred into
clinical practice which is crucial for alemtuzumab with ne-
cessary longterm monitoring [40].
Methods/Design
Study design
TREAT-MS is a prospective, multicenter, non-interventional
long-term study. Data are collected from around 300
neurologists in specialized MS centers (clinical centers or
outpatient departments) in all parts of Germany. Patients
are eligible for documentation, if they fulfill the EMA label.
The study does not stipulate any diagnostic or treatment
procedures.
Study population
Alemtuzumab has not been administered to minors
(<18 years). Patients have received a diagnosis of active
RRMS from their neurologists. As non-interventional
study (NIS) no specific inclusion resp. exclusion criteria
apply in order to avoid selection bias in this real world
study beyond the relative or absolute contraindications
of the alemtuzumab EMA label [41].
Study flow
Figure 1 and the Table 1 provide an overview on the
study flow and the items to be documented. At the base-
line visit, current and retrospective data on the patient
and MS are collected; thereafter patients are followed up
in a prospective way. All patients will be monitored for
60 months after the first administration altogether, and
for almost 48 months after the second administration of
alemtuzumab to vouchsafe a complete realization of the
risk management plan. Demographic and clinical data of
participants are gathered from medical examinations and
other sources (e.g. MS nurse). Information about patient-
reported outcomes is completed by participants during
their visits in clinics and centers in the presence of a
health care professional. Neurologists and MS nurses will
be guided by the MSDS 3D-Lemtrada-TREAT-MS mod-
ule through the entire management of treatment, includ-
ing monitoring of the first and second infusions, necessary
examinations, and regular laboratory screenings.
Documentation by clinicians
Treatment preparations Taking into consideration the
well-known side-effects and contraindications of alemtu-
zumab, a detailed patient history and physical examination
should be performed to exclude possible contraindications
[28]. Recommended lab tests before starting treatment
with alemtuzumab should be done before every alemtuzu-
mab infusion later on. The vaccination status is checked at
baseline. Lacking vaccinations (e.g., varicella) are to be ad-
ministered no later than six weeks before start of alemtu-
zumab treatment. Tests for various infectious agents
(tuberculosis, hepatitis B and C, varicella-zoster and JC
virus) are performed to avoid infectious disease complica-
tions after infusion.
A specific interest of TREAT study will be the different
pretreatment status of the patients as the strategy how to
initiate the treatment with alemtuzumab depends on
pretreatment status of the patient. As direct switching
from interferon-beta or glatiramer Acetate to alemtuzu-
mab is possible, prior therapy with natalizumab represents
a special situation as the switching protocol depends on
the actual PML risk which is closely linked to the JCV
status and natalizumab treatment duration [12, 28].
Fig. 1 Study design
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Table 1 Study schedule
Control examination: month after start of treatment
1 2 3 4 5 6 7 8 9 10 11 12
13 14 15 16 17 18 19 20 21 22 23 24
Treatment 25 26 27 28 29 30 31 32 33 34 353 36
1st infusion 37 38 39 40 41 42 43 44 45 46 47 48
baseline 2nd infusion 49 50 51 52 53 54 55 56 57 58 59 60
Singed declaration of informed consent x
Patient characteristics (age and sex) x
MS anamnesis
- Diagnosis x
- Date of first diagnosis (RRMS) x
- Number of relapses in the last year and the year before x
- Comorbidities including fatigue and depression x
- Previous MS basis therapy x
Relapses during observation time
- Number x x x x x x x x x x x x x
- Number of relapses treated with cortisone x x x x x x x x x x x x x
EDSS (Expanded Disability Status Scale) x x x x x
SDMT (Symbol Digit Modality Test) x x x
PRIM US (Patient-Reported Indices for MS) x x x
EuroQol (ED-SD) x x x
Responding to treatment/clinical evaluation
CGI (Clinical Global Impressions Scale):
- Details provided by the physician x x x
- Details provided by the patient x x x
Economic parameters
WPAI (Work productivity and Activity Impairment Questionnaire) x x x
Examinations before and after therapy with Lemtrada®
Pre-existing illnesses x
Bodily examination x
Total and differential blood count x x x x x x x x x x x x x x
Serum creatine level x x x x x x x x x x x x x
Urine status x x x x x x x x x x x x x




Test for tuberculosis x
Test for hepatits B and C x
Tests for varicella-zoster virus x
Test for JC virus x
Contraception/exclusion of an existing pregnancy x x
Adverse events since therapy start x x x x x x x x x x x x
MRI (new T2 or Gd(+)-lesions) x if MRT examinations are performed routinely
Baseline at least 6 weeks prior to first alemtuzumab injection, if vaccinations need to be made
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Disease progression and clinical monitoring Before
commencement of treatment, history and disease course
of the patient’s MS, including previous therapeutic inter-
ventions, are assessed. In particular, the number of re-
lapses in the last year and the year before and
comorbidities are documented. The number of relapses
is an effectiveness criterion in this study, and thus
closely followed up. A relapse is defined as an episode of
neurological symptoms that happens at least 30 days after
any previous episode began, lasts at least 24 h and is not
attributable to another cause and occurs in the absence of an
infection or fever. It has to be accompanied by either new
clinical signs, i.e. changes in the neurological examination, or
an increase in the disability (EDSS) score. If magnetic
resonance tomography (MRI) examinations are performed
routinely, at every visit results are documented. This includes
number of lesions in T2-weighted MRI and gadolinium-
enhancing lesions due to analysis of the local radiologist.
Alemtuzumab application Alemtuzumab infusion is doc-
umented in a detailed way including concomitant medica-
tion and adverse events.
Laboratory monitoring Total and differential blood
count, serum creatinine and urine status are evaluated
every month after alemtuzumab infusion to gain reference
values for measuring the impact of alemtuzumab adminis-
tration on these health parameters. In addition, thyroid
function is assessed every 3 months using TSH. All tests
are repeated for 4 years after the last alemtuzumab infusion,
and the results are documented in the system.
Further instruments applied by physicians include the
Expanded Disability Status Scale (EDSS) and the Clinical
Global Impression (CGI) (severity) until termination of
the observation phase.
Expanded disability status scale The EDSS is a
clinician-rated scale based on neurological history and
physical examination, which is used to determine the
degree of neurological disability in patients with multiple
sclerosis [42–44]. As part of the EDSS Neurostatus, eight
functional systems are assessed: pyramidal, cerebellar,
brainstem, sensory, bowel and bladder, visual, cerebral and
other. The rating is performed by certified health care pro-
fessionals, most usually a neurologist. It normally takes
20-30 min to complete the rating. The EDSS gives a score
from 0 (normal neurological examination) to 10 (death
from multiple sclerosis), with half points from 1 upwards.
In the TREAT study, EDSS and functional system scores
are documented.
Clinical global impression The CGI, developed by the
National Institute of Health originally for use in psychiatry,
is a three-item scale used to assess treatment response [45].
The present study uses item 2 only, on seven-point scale (1
= very much improved to 7 = very much worse). The CGI
is robust, simple (clinically understandable), and sensitive
to change.
Patient-related self-reported outcomes
The study puts great emphasis on the documentation of
patient-related outcomes including functionality, quality
of life and ability to work. Thus, patients are requested
to fill out various questionnaires at inclusion and at
6-month intervals thereafter.
Symbol digit modality test The SDMT, developed by
Wechsler et al., is a neuropsychological test measuring
attention [45]. It is brief, easy to administer, and has dem-
onstrated remarkable sensitivity in detecting not only the
presence of brain damage, but also changes in cognitive
functioning over time and in response to treatment. The
SDMT involves a simple substitution task: Using a refer-
ence key, the test taker has 90 s to pair specific numbers
with given geometric figures. Responses can be written or
given orally, and administration time is just five minutes
for either response mode.
Patient-reported outcome indices for MS PRIMUS,
published in 2009 by Galen Research [46], is a disease spe-
cific patient-reported outcome questionnaire that measures
quality of life (QoL) of MS patients. The questionnaire con-
sists of three scales: quality of life (22 questions), symptoms
(8 questions) and activity status (15 questions), which can
either be used by the patient together or as standalone
measures. On the QoL scale, questions are to be answered
with yes or no, and items are summed to yield a total score
ranging from 0 to 22 (with high scores indicating low QoL).
The activity limitations scale contains 15-items describing
specific physical tasks, and respondents rate the degree to
which they are able to perform the tasks on a three point
scale. Here, items are summed to give a total score that can
range from 0 to 30, with higher scores representing greater
activity limitation. Both scales have been shown to be unidi-
mensional and to have good reproducibility and validity in
a number of languages [47].
Euro-Qol 5D-3 L The EQ-5D questionnaire, developed by
the EuroQol group [48], is a standardized measure of health
status, applicable to a wide range of health conditions and
treatments. The descriptive system of health-related quality
of life states consists of five dimensions (mobility, self-care,
usual activities, pain/discomfort, anxiety/depression) each of
which can take one of five responses. The responses record
five levels of severity (no problems/slight problems/moder-
ate problems/severe problems/extreme problems) within a
particular EQ-5D dimension. In addition, self-assessed qual-
ity of life is measured using a 0–100 visual analogue scale.
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The EQ-5D provides a simple descriptive profile and a
single index value for health status that can be used in the
clinical and economic evaluation of health care as well as in
population health surveys [49].
Work productivity and activity impairment question-
naire The WPAI:MS questionnaire consists of 6 questions
(1 = currently employed; 2 = hours missed due to health
problems; 3 = hours missed other reasons; 4 = hours actu-
ally worked; 5 = degree health affected productivity while
working (using a 0 to 10 Visual Analogue Scale (VAS)); 6
= degree health affected productivity in regular unpaid
activities (VAS). The recall period for the questions 2 to 6
is seven days. Thus, the questionnaire measures absentee-
ism, presenteeism as well as the impairments in unpaid
activity because of health problems during the past seven
days [50]. It has been validated to quantify work impair-
ments for numerous diseases such including asthma, psor-
iasis, irritable bowel syndrome, ankylosing spondylitis and
Crohn’s disease. In addition, the WPAI questionnaire has
been used to compare work impairments between treat-
ment groups in clinical (studies and) trials or between
subjects with different disease severity levels.
Adverse events reporting At every visit, patients are
asked for the occurrence of adverse events (AEs). As alem-
tuzumab is a product under special observation (due to its
novelty and immunological effects), each adverse effect oc-
curring during alemtuzumab therapy must be reported, ir-
respective of a causal connection attributed to
alemtuzumab. Time, duration, intensity and outcomes of
each AE are documented. Further, the treating phys-
ician is asked to assess in terms of a causal connection
to alemtuzumab treatment. Severe adverse events are
life-threatening or lead to death, hospitalization, to last-
ing or severe disability, incapacity or congenital anom-
aly. Adverse events are documented locally in the
MSDS 3D-Alemtuzumab-TREAT-Module (see below)
and sent automatically to the pharmacovigilance de-
partment of Sanofi-Aventis/Genzyme. A list of AEs of
special interest is presented in Table 2.
Risk Management Plan (RMP) For prescribing doctors
and medical specialists who participate in the care for MS
patients treated with alemtuzumab, a risk management
plan was developed by the drug manufacturer, and ap-
proved by the regulatory authorities. It informs precisely
about the risks and possible severe adverse effects which
can occur during alemtuzumab treatment. Moreover, in-
formation is provided to physicians about the required
regular tests to ensure clinical vigilance. The documenta-
tion system MSDS 3D (see next section) will be used to
document all data from the patient according the RMP
and expert information for alemtuzumab.
MS documentation system for physician, nurse and patient
(MSDS3D)
Due to the chronicity of MS and its long-term treatment
including a post-treatment observation phase, an elec-
tronic data recording system which captures all steps of
the treatment on a timeline and allows interaction of the
participants of the treatment process (physician, nurse,
and patient) is very useful or even required for optimal
care. Also, large amounts of data arise in the treat-
ment process and should be managed in a systematic
way [51].
For these tasks, the MSDS3D software has been devel-
oped at Dresden University of Technology (Germany)
[52, 53]. It emerged from MSDS Clinic which gathers
the personal data of the patient, her/his treatment details
and disease course, data from clinical examinations and
clinical scores [54]. The software interface presents all
procedures in clickable boxes which lead to data entry
menus. Then, upon authorization, a MS nurse or neur-
ologist can enter the relevant data (e.g., EDSS, adverse
effects).
MSDS3D provides a standardized management and docu-
mentation for treatment and disease course of the patient; it
can also be used to import data into various database sys-
tems as MS BASE [55]. In addition to the features of MSDS
Clinic, information can be directly shared with the patient
and feedback can be received from him. The patient can
deliver information by using a touchscreen in the neuro-
logical center, or he can log into the system from his home
computer to enter information or reply to queries. For
example, by solving a questionnaire about the symptoms of







Infusion-associated reactions Anaphylactic reactions
Infections Opportunistic infections,
disseminated infections






Liver disease Elevated transaminases





Particular attention should be given to diseases highlighted in bold
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adverse effects in immunomodulatory treatments of MS the
patient can help detect severe AEs such as PML or Good-
pasture Syndrome early [56].
In addition to MSDS3D, the online-based MSDS3D-
TREAT electronic case report form (eCRF) (Fig. 2a to c)
can be used to document patient data, the local MSDS3D
software and the MSDS3D web tool are linked to the same
database (Fig. 3). These are labelled with a code that does
not permit identification of the patient; only physicians or
people authorized by the project administration possess
access rights to this code.
The MSDS3D interface introduces a feature known from
eCRFs. The user sees a vertical timeline, while the proce-
dures which have to be executed during the treatment
process are arranged horizontally and shown as clickable
‘procedure boxes’. These lead to input menus for the
procedure which is to be executed, e.g. EDSS screening or
registration of adverse effects.
Moreover, MSDS3D can create physician’s reports either
through entering free text or by using text modules. The
system was modified to document immunomodulatory
treatments such as alemtuzumab, natalizumab and fingoli-
mod. Before a drug is administered, e.g. as an infusion, the
system asks for all relevant health checks, and after all
checks have been performed successfully, the treatment is
authorized by the neurologist. In the visit module, specific
instruments (categorized tasks) are attributed to every
visit. Color marks and other signs point to the processing
stage of the tasks. In addition, the toolbar contains buttons
for concurrent medications and queries about data docu-
mented within the system. Red and blue colors show open




Fig. 2 a to c. MSDS 3D TREAT-MS module: start page
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Different MS treatment cohorts have been already
followed up using MSDS3D (eg. Fingolimod [57, 58], Natali-
zumab [56, 59, 60]) which will allow comparisons between
different treatment groups. Identification and mitigation of
biases and careful consideration of study power are key
factors for designing appropriate RWE studies. Various
biases exist, which require careful consideration in selecting
appropriate comparators, patient populations, data sources,
outcomes, and statistical analyses [36].
Data management and statistical aspects
Data management has been described in a separate data
management plan, which includes a data validation plan.
A population size of 3200 patients means that adverse
events with an incidence of 1:1068 or more will occur at
least once in the alemtuzumab patient population.
For the portion of patients with a premature termin-
ation of the risk management plan, 95 % confidence in-
tervals according to the method of Clopper and Pearson
are determined. Proportional hazards model will be used
to assess whether certain patient subgroups are more
likely than other to terminate the RMP early. In general,
for continuous variables numbers of patients, mean and
standard deviation, the five point summary (minimum,
lower quartile, median, upper quartile, maximum) and
possibly further appropriate percentiles will be deter-
mined. For categorical variables absolute and percentage
frequencies will be calculated.
For means and estimated probabilities – and, if signifi-
cant, for further parameter as well – 95 % confidence
intervals will be determined. The evaluations will also be
performed for subgroups which are defined before in the
statistical analysis plan. Depending on the number of
subgroups defined in the plan the confidence level will
possibly be raised. The evaluations of the used question-
naires SDMT, EQ-5D, PRIMUS, CGI-S (versions for phys-
ician and patient) and WPAI are performed according to
validated and published algorithms. All statistical evalua-
tions are of exploratory nature.
Timelines The study started in November 2014 and re-
cruitment is planned until December 2016, however, it will
be stopped as soon as a sufficient number of patients have
Fig. 3 MSDS3D data transfer to the TREAT DATABASE server via internet-based or locally installed MSDS3D system
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been enrolled. Observation of patients and documentation
will continue until September 2022.
Discussion
In recent years, innovative immunotherapies have offered
new treatment options, better disease control and improved
the quality of life in patients with MS. With the introduc-
tion of natalizumab in 2006 and fingolimod in 2011 as ther-
apies for RRMS, safety aspects became more prominent. In
order to address those comprehensively, clearly defined
cooperations between MS specialists and doctors from
other disciplines, such as radiologists, cardiologists or oph-
thalmologists needed to be established. In 2013, with teri-
flunomide and alemtuzumab, further immunotherapeutics
for MS were approved, that require before and during
application regular check-ups to ensure safe use. The most
extensive catalogue of requirements for pharmacovigi-
lance arises in the application of the new anti-CD52
antibody alemtuzumab, which has received a broad la-
belling in Europe which does not exclude first-line use.
On top of the body of evidence from 1500 patients that
received alemtuzumab in the randomized controlled trials
(CAMMS223 [23], CARE-MS I [24] and CARE- II [25]),
the clinical experience with the agent has substantially
increased since market introduction. Nevertheless there
are only few reports yet on the long-term use of the drug
in the routine of physicians and MS centers. TREAT-MS
will fill this gap, and will document physician and patient
experience in daily clinical practice for 6 years. Data in this
non-interventional study will be collected on a widely
unselected patient population eligible for alemtuzumab
treatment. It is expected that compared to the clinical
studies, patients with more concomitant diseases and/or
more concomitant medications will be documented. To-
gether with the high patient numbers and long follow-up
period, a substantial number of patient years will be docu-
mented and the option for relevant subgroup analyses
provided.
As the registry protocol was developed based on the
risk management plan for alemtuzumab, by participation
in the study, physicians are reminded about the investi-
gations and precautions which are needed for the safe
use of this potent immunological drug [28]. Thus, the
study serves the additional purpose to optimize the drug
utilization according to the conditions specified by the
labelling.
The documentation system MSDS3D has been shown to
be efficient to guide physicians through the study proce-
dures and to collect the relevant information in clinical
practice and for the use in previous non-interventional
studies such as PANGAEA [57]. It interactively collects
data, but also assists neurologists in the execution of com-
plex processes required for comprehensive management
of MS patients.50
The planned number of 3200 patients in TREAT-MS
are recruited from centers in all parts of the country and
different types of centers (office-based, various types and
sizes of hospitals), which makes the study representative
for the situation in Germany. Thus – apart from tripli-
cating the number of documented individuals treated
with alemtuzumab– the evidence of benefits and risks of
alemtuzumab for patients as well as for physicians will
appear in much higher resolution and depth when the
study ends. A two- or three-times longer post-treatment
observation phase (compared with the pre-market trials)
with monthly clinical checks will also contribute to this
effect and lead to more secure information of the inci-
dence of secondary autoimmune diseases and other
adverse effects.
TREAT could serve in future as part of a personalized
medicine approach in MS, where MS patients are charac-
terized by a detailed clinical profiling and followed up by
prospective longterm documentation [61]. This data can
be used to analyze treatment response patterns of alemtu-
zumab and allow personalized treatment approaches. Pre-
dictive models could be implemented using this data [62].
So TREAT data will assist in complex treatment decisions
in future. It will be interesting to investigate different base-
line profiles (de novo patients, patients escalated from first
line therapies, patients switching from escalation therap-
ies) and treatment response and safety of alemtuzumab.
Among the limitations of TREAT-MS as an non-
interventional, open study is the absence of blinding,
neither on the patients’ nor on the physicians’ side. Fur-
ther, there is no comparator group. The expectation to
treat or be treated with a novel anti-MS drug might lead
to a higher amount of reported positive effects than ob-
served in a study with blinded subjects or physicians.
Moreover, physicians may assign patients to the study
based on the severity of their disease, the observation
that they did not respond well to conventional drugs, or
the presence of complex comorbidities; this might bias
study results. Through such possibly biased allocation of
participants, assessing the correlation between treatment
and outcomes will be difficult.
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